Cerus traded at $2.15 this Wednesday February 11th, decreasing $0.08 or 3.59 percent since the previous trading session. Looking back, over the last four weeks, Cerus lost 5.29 percent. Over the last 12 months, its price rose by 25.00 percent. Looking ahead, we forecast Cerus to be priced at 1.81 by the end of this quarter and at 1.65 in one year, according to Trading Economics global macro models projections and analysts expectations.
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.